MIM
JAZZ icon

MetLife Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

MetLife Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.27M Buy
30,158
+307
+1% +$67.3K 0.03% 484
2026
Q1 		$5.64M Buy
29,851
+201
+0.7% +$35.1K 0.03% 573
2025
Q4 		$5.04M Sell
29,650
-1,488
-5% -$228K 0.02% 620
2025
Q3 		$4.1M Sell
31,138
-2,012
-6% -$241K 0.02% 732
2025
Q2 		$3.52M Sell
33,150
-395
-1% -$42.9K 0.02% 733
2025
Q1 		$4.16M Sell
33,545
-531
-2% -$69.3K 0.02% 709
2024
Q4 		$4.2M Buy
34,076
+2,162
+7% +$255K 0.02% 663
2024
Q3 		$3.56M Sell
31,914
-1,242
-4% -$136K 0.02% 722
2024
Q2 		$3.54M Sell
33,156
-2,700
-8% -$297K 0.02% 682
2024
Q1 		$4.32M Sell
35,856
-908
-2% -$111K 0.03% 572
2023
Q4 		$4.52M Sell
36,764
-692
-2% -$86.4K 0.03% 515
2023
Q3 		$4.85M Sell
37,456
-2,159
-5% -$288K 0.04% 417
2023
Q2 		$4.91M Buy
39,615
+1,032
+3% +$139K 0.04% 451
2023
Q1 		$5.65M Sell
38,583
-1,033
-3% -$153K 0.04% 382
2022
Q4 		$6.31M Sell
39,616
-603
-1% -$88.4K 0.05% 329
2022
Q3 		$5.36M Sell
40,219
-280
-0.7% -$42.6K 0.04% 375
2022
Q2 		$6.32M Buy
40,499
+775
+2% +$119K 0.05% 313
2022
Q1 		$6.18M Buy
39,724
+9,935
+33% +$1.44M 0.04% 397
2021
Q4 		$3.8M Buy
29,789
+412
+1% +$54.1K 0.03% 541
2021
Q3 		$3.83M Sell
29,377
-652
-2% -$98.5K 0.03% 505
2021
Q2 		$5.33M Buy
30,029
+935
+3% +$162K 0.05% 360
2021
Q1 		$4.78M Sell
29,094
-1,394
-5% -$229K 0.04% 411
2020
Q4 		$5.03M Sell
30,488
-1,265
-4% -$188K 0.05% 356
2020
Q3 		$4.53M Buy
+31,753
New +$3.94M 0.05% 346
2019
Q2 		– Sell
-81
Closed -$11.6K – 2522
2019
Q1 		$11.6K Buy
81
+1
+1% +$130 ﹤0.01% 2496
2018
Q4 		$9.92K Sell
80
-1
-1% -$148 ﹤0.01% 2378
2018
Q3 		$13.6K Buy
+81
New +$13.9K ﹤0.01% 2408

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

MetLife Investment Management's JAZZ Position: Q2 2026 in Review

MetLife Investment Management increased its Jazz Pharmaceuticals (JAZZ) stake by 1% in Q2 2026, buying an estimated $67.3K and bringing the position to 30,158 shares worth $7.27M. The position accounts for 0.03% of the portfolio, ranked #484.

MetLife Investment Management first reported a position in JAZZ in Q3 2018 and has held it in 27 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • MetLife Investment Management held 30,158 shares of Jazz Pharmaceuticals worth $7.27M as of Q2 2026.
  • MetLife Investment Management bought 307 Jazz Pharmaceuticals shares in Q2 2026, an estimated $67.3K.
  • Jazz Pharmaceuticals made up 0.03% of MetLife Investment Management's portfolio in Q2 2026, its #484 holding.
  • MetLife Investment Management first reported a position in Jazz Pharmaceuticals in Q3 2018 and has held it in 27 quarters since.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.